过敏科

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. New Mast Cell Lines from Patients with Systemic Mastocytosis

   Rochester, Minn.

   The purpose of this study is to attempt to establish new mast cell lines from patients with systemic mastocytosis using peripheral blood and/or bone marrow.

2. Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of Sulfonamide Allergy

   Rochester, Minn.

   The aim of this study is to study the efficacy and safety of our short and long one-day protocols for TMP-SMX graded administration in hematologic malignancy, hematopoietic stem cell transplant, and solid organ transplant patients.    

3. Analysis of Group 2 Innate Lymphoid Cells in Peripheral Blood

   Rochester, Minn.

   The primary objective of this study is to investigate the contribution of group 2 innate lymphoid cells (ILC2s) to the immunologic mechanisms of chronic airway diseases.

4. Prognostic Risk Evaluation for Hypereosinophilic Syndrome (HES) and Idiopathic Hypereosinophilia (IHE) and the Role of Next-generation Sequencing

   Rochester, Minn.

   The purpose of this study is to:

   1. To identify predictors of inferior overall survival in HES/IHE patients including molecular parameters using next-generation sequencing performed at the point of clinical care
   2. To apply the previously proposed prognostic model that included myeloid-relevant gene mutations to identify high-risk HES/IHE patients for closer monitoring

5. A Study to Evaluate the Effectiveness and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

   Rochester, Minn.

   This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study comprises 2 distinct periods (together defined as the 'main study'): A 24-week, DB treatment period, during which patients will be randomised to receive either benralizumab or placebo, in addition to prior stable HES background therapy, and an open-label (OLE) treatment period, during which all patients will receive benralizumab. The primary database lock (DBL) will occur when at least 47 patients have had their first HES worsening/flare event and all randomised patients have been followed up for the 24-week DB treatment period. The target patient population is male and female patients 12 years of age and older with symptomatic active HES. Approximately 120 eligible patients will be randomised at a 1:1 ratio to receive either benralizumab or matching placebo.

6. A Study of the Effects of Preterm Birth on Lung Disease and Innate Immunity Later in Life

   Rochester, Minn.

   The primary purpose of this study is to investigate the cytokine responses of blood ILC2s from preterm children by collecting peripheral blood at age 5-10 years from children born either preterm or at term, and to analyze the functions of their circulating ILC2s in vitro.

    

7. A Study to Evaluate the Effect of Medical Intervention on Sinonasal Inflammation in Patients with Chronic Sinusitis, Nasal Polyps and Positive Sinus Culture

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to compare change in SNOT-22 score in patients who received medication therapy such as oral antibiotics, topical antibiotics, oral corticosteroids, topical corticosteroids, leukotriene receptor antagonist, and interleukin 5 receptor antagonist following endoscopic sinus surgery versus control in patient with chronic sinusitis with nasal polyps and a positive culture.

8. Factors Contributing to Underutilization of Epinephrine for Allergy Anaphylaxis

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to evaluate the rate of compliance for having an emergency epinephrine autoinjector readily accessible in adults with allergies, and to determine factors that negatively influence adults with allergies for having an emergency epinephrine autoinjector readily accessible.

以下为当前的临床试验。

按院区、状态和其他条件筛选该研究列表。

1. New Mast Cell Lines from Patients with Systemic Mastocytosis

   Rochester, Minn.

   The purpose of this study is to attempt to establish new mast cell lines from patients with systemic mastocytosis using peripheral blood and/or bone marrow.

2. Trimethoprim-sulfamethoxazole Graded Administration in Oncology, Hematopoietic Stem Cell Transplant, and Solid Organ Transplant Patients with a History of Sulfonamide Allergy

   Rochester, Minn.

   The aim of this study is to study the efficacy and safety of our short and long one-day protocols for TMP-SMX graded administration in hematologic malignancy, hematopoietic stem cell transplant, and solid organ transplant patients.    

3. Analysis of Group 2 Innate Lymphoid Cells in Peripheral Blood

   Rochester, Minn.

   The primary objective of this study is to investigate the contribution of group 2 innate lymphoid cells (ILC2s) to the immunologic mechanisms of chronic airway diseases.

4. Prognostic Risk Evaluation for Hypereosinophilic Syndrome (HES) and Idiopathic Hypereosinophilia (IHE) and the Role of Next-generation Sequencing

   Rochester, Minn.

   The purpose of this study is to:

   1. To identify predictors of inferior overall survival in HES/IHE patients including molecular parameters using next-generation sequencing performed at the point of clinical care
   2. To apply the previously proposed prognostic model that included myeloid-relevant gene mutations to identify high-risk HES/IHE patients for closer monitoring

5. A Study to Evaluate the Effectiveness and Safety of Benralizumab in Patients with Hypereosinophilic Syndrome (HES)

   Rochester, Minn.

   This is a multicentre, randomised, double-blind (DB), parallel-group, placebo-controlled, 24-week Phase III study to compare the efficacy and safety of benralizumab versus placebo administered by SC injection Q4W in patients with hypereosinophilic syndrome (HES). This study comprises 2 distinct periods (together defined as the 'main study'): A 24-week, DB treatment period, during which patients will be randomised to receive either benralizumab or placebo, in addition to prior stable HES background therapy, and an open-label (OLE) treatment period, during which all patients will receive benralizumab. The primary database lock (DBL) will occur when at least 47 patients have had their first HES worsening/flare event and all randomised patients have been followed up for the 24-week DB treatment period. The target patient population is male and female patients 12 years of age and older with symptomatic active HES. Approximately 120 eligible patients will be randomised at a 1:1 ratio to receive either benralizumab or matching placebo.

6. A Study of the Effects of Preterm Birth on Lung Disease and Innate Immunity Later in Life

   Rochester, Minn.

   The primary purpose of this study is to investigate the cytokine responses of blood ILC2s from preterm children by collecting peripheral blood at age 5-10 years from children born either preterm or at term, and to analyze the functions of their circulating ILC2s in vitro.

    

7. Factors Contributing to Underutilization of Epinephrine for Allergy Anaphylaxis

   Jacksonville, Fla., Rochester, Minn.

   The purpose of this study is to evaluate the rate of compliance for having an emergency epinephrine autoinjector readily accessible in adults with allergies, and to determine factors that negatively influence adults with allergies for having an emergency epinephrine autoinjector readily accessible.

8. A Study to Evaluate the Effect of Medical Intervention on Sinonasal Inflammation in Patients with Chronic Sinusitis, Nasal Polyps and Positive Sinus Culture

   Jacksonville, Fla., Scottsdale/Phoenix, Ariz.

   The purpose of this study is to compare change in SNOT-22 score in patients who received medication therapy such as oral antibiotics, topical antibiotics, oral corticosteroids, topical corticosteroids, leukotriene receptor antagonist, and interleukin 5 receptor antagonist following endoscopic sinus surgery versus control in patient with chronic sinusitis with nasal polyps and a positive culture.